whytestocks
6 years ago
News: $BIOS BioScrip, Inc. Provides Merger Update
DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Optio...
Read the whole news https://marketwirenews.com/news-releases/bioscrip-inc-provides-merger-update-8042964.html
whytestocks
6 years ago
News: $BIOS Report: Developing Opportunities within Macy's, Leggett & Platt, Tyler Technologies, BioScrip, DXC Technology, and STERIS plc - Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Macy's, Inc. (NYSE:M), Leggett & Platt, Incorporated (NYSE:LEG), Tyle...
Find out more https://marketwirenews.com/news-releases/report-developing-opportunities-within-macy-s-leggett-platt-tyler-technologies-bioscrip-dxc-technology-and-steris-plc-future-expectations-projections-moving-into-2019-7414554.html
UFO
7 years ago
Insider selling!
UFO
Statement of Changes in Beneficial Ownership (4)
Date : 09/19/2017 @ 4:00PM
Source : Edgar (US Regulatory)
Stock : Bioscrip, Inc. (MM) (BIOS)
Quote : 2.55 -0.14 (-5.20%) @ 4:41PM
Statement of Changes in Beneficial Ownership (4)
Print
Alert
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Bronfein Michael G 2. Issuer Name and Ticker or Trading Symbol
BioScrip, Inc. [ BIOS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O BIOSCRIP, INC., 1600 BROADWAY, SUITE 950 3. Date of Earliest Transaction (MM/DD/YYYY)
9/15/2017
(Street)
DENVER, CO 80202
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.0001 Par Value 9/15/2017 S 27000 D $2.6938 (1) 129669 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
(1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions in prices ranging from $2.68 to $2.71, inclusive. The reporting person undertakes to provide BioScrip, Inc., any security holder of BioScrip, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Bronfein Michael G
C/O BIOSCRIP, INC.
1600 BROADWAY, SUITE 950
DENVER, CO 80202 X
Signatures
/s/ Michael G. Bronfein 9/19/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.